Baxter to Host Annual Meeting of Stockholders in Virtual Format Mar 25, 2026 4:30 PM Eastern Daylight Time Baxter to Host Annual Meeting of Stockholders in Virtual Format Share DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, May 5, 2026 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2026 Annual Meeting. Online access to the 2026 An ...

EU regulator warns of shortage in Baxter's cancer treatment until early 2027 | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A European Union flag flutters outside the European Commission headquarters in Brussels, Belgium Februrary 26, 2026. REUTERS/Yves Herman/File Photo Purchase Licensing Rights, opens new tab The European Medicines Agency said the shortage was due to a technical disruption at Baxter's contract manufacturing sit ...

Baxter International Inc. (BAX), headquartered in Deerfield, Illinois, develops and provides a portfolio of healthcare products. With a market cap of $8.8 billion,  the company develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The company's products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and researc ...

Baxter Announces CFO Transition Baxter Announces CFO Transition Share Baxter has named Anita Zielinski as interim CFO, effective immediately, while the company conducts its search to fill the role. Ms. Zielinski joined Baxter in 2025 as senior vice president, chief accounting officer and controller, and will continue with these responsibilities in addition to serving as interim CFO. She joined Baxter from Sysco Corporation, where she most recently served as senior vice president and CFO, U.S. Foodservice Op ...

Core Viewpoint - The discussion centers around the impact of the Middle East conflict on oil prices and the size of the business in that region, which is a critical concern for global multinationals [1] Group 1 - Investors are interested in understanding the scale of the business in the Middle East, specifically whether it falls below certain thresholds such as sub-5 or sub-2 [1]

Summary of Baxter International FY Conference Call (March 11, 2026) Company Overview - **Company**: Baxter International (NYSE:BAX) - **Date of Conference**: March 11, 2026 - **Key Speakers**: Joel Grade (EVP, CFO), Kevin Moran (Investor Relations) Key Points Industry and Market Context - **Geopolitical Impact**: Baxter has minimal exposure to the Middle East, with revenue described as "sub 2" million, indicating limited business operations in that region [11][13][15] - **Energy Costs**: The company's exposure to oil price fluctuations has decreased to less than half compared to previous assessments made during the 2022 investor day. Previously, a $10 increase in oil prices would impact Baxter by $25 million; this impact is now less than half of that [18][20][36] Financial Performance and Guidance - **Operational Changes**: The company has undergone significant restructuring, including the sale of BPS and verticalization of its business structure, which is expected to enhance operational efficiency and predictability [52][54] - **New Operating Model**: The introduction of the Growth and Performance Systems (GPS) aims to improve goal setting, KPI tracking, and overall operational cadence, leading to better forecasting and margin expansion over time [54][55] - **Product Performance**: The Advanced Surgery and Hospital Solutions Technologies (HST) segments have shown strong performance, with a solid order book and good global demand for differentiated products [63][64] Business Segments - **Advanced Surgery**: Continues to produce well-received products with strong global demand, expected to remain a margin-accretive business [63] - **HST**: Experienced a good year, with a focus on innovation and new product launches, including the Connex 360 monitoring device and the Dynamo stretcher [90][94] - **Pharmaceuticals**: Drug compounding is a strong growth area, although challenges remain in the injectables and anesthesia space due to operational issues and market conditions [71][72] Challenges and Risks - **Product Sales**: Baxter does not expect to sell Novum pumps through 2026 due to regulatory uncertainties, although sales of Spectrum pumps remain strong [82][88] - **Margin Pressures**: Higher inventory costs and tariff impacts are expected to affect margins in the first half of 2026, but improvements are anticipated in the second half due to restructuring and new product launches [97][98][100] Strategic Focus - **Innovation and Customer-Centric Approach**: The company emphasizes innovation and customer-centric product development as key drivers for future growth [94][95] - **Operational Efficiency**: Efforts to streamline management layers and reduce infrastructure costs are aimed at creating a more agile organization [55][60] Conclusion - Baxter International is navigating a complex market environment with strategic changes aimed at enhancing operational efficiency and product innovation. The company is positioned for growth in key segments, although it faces challenges related to regulatory issues and margin pressures. The focus on GPS and restructuring is expected to yield positive results in the long term.

Core Viewpoint - The article discusses the author's long-term investment strategy focusing on value over growth, highlighting the experience gained from witnessing significant market events like the dot-com bubble [1]. Group 1 - The author has been contributing to investment websites since 2011, indicating a strong background in financial analysis and market trends [1]. - The author holds a Series 7 and 63 license, showcasing a formal qualification in securities trading [1]. - The author has experience in a tech-focused retail brokerage during the dot-com bubble, providing insights into market volatility and investment strategies [1]. Group 2 - The author has a beneficial long position in BAX shares, indicating confidence in the company's future performance [2]. - The article expresses the author's personal opinions and does not involve compensation from any company mentioned, ensuring an unbiased perspective [2]. - There is no business relationship with any company whose stock is mentioned, reinforcing the independence of the analysis [2].

Core Insights - The article does not provide any specific information or insights regarding a company or industry [1] Summary by Categories - No relevant content available for summarization [1]

Summary of Baxter International 2026 Conference Call Company Overview - **Company**: Baxter International (NYSE: BAX) - **Date of Conference**: February 26, 2026 Key Industry Insights - **Medtech Fundamentals**: The underlying fundamentals of the medtech industry are described as solid and stable, despite stock performance concerns. Patient volumes and procedure volumes are in a decent place, with no significant hyperinflationary pressures noted [12][13]. - **IV Solutions Market**: Demand for IV solutions has decreased by approximately 10-15% from pre-hurricane levels, establishing a new baseline for the market. This decline is attributed to changes in clinical practices following a hurricane [13][14][41]. Company-Specific Developments - **Leadership Changes**: The arrival of a new CEO, Andrew, is seen as timely for Baxter, allowing the company to build on a clearer operational foundation after recent distractions from divestitures [20][21]. - **Operational Model**: The introduction of a new operating model (GPS) aims to enhance consistency in operations and performance tracking. This model is expected to lead to improved operational predictability [22]. - **Verticalization Strategy**: Baxter is evolving its business structure to allow for end-to-end ownership of profit and loss (P&L), moving away from a country-led structure. This change is intended to streamline decision-making and improve accountability [29][30][37]. Financial Performance and Guidance - **2026 Guidance**: The guidance for 2026 is described as prudent, factoring in challenges and opportunities. It does not include any sales from the Novum product, which is under a voluntary shipping hold [101][103]. - **Margin Expectations**: The company anticipates sequential improvement in gross and operating margins throughout 2026, particularly in the second half of the year, as operational issues are resolved [116][118]. - **Capital Allocation**: Baxter is focused on deleveraging its balance sheet, targeting a debt-to-EBITDA ratio of three times by the end of the year. Internal investments in R&D and capital spending remain a priority [131][134]. Product Innovations - **New Products**: The Connex 360, a next-generation monitoring device, and the Dynamo, a connected stretcher, are highlighted as key innovations expected to drive growth in 2026. Customer feedback has been positive for these products [76][78]. Challenges and Risks - **Supply Chain Issues**: The company has faced supply challenges in its pharmaceutical business, which have impacted production and market performance. These issues are expected to improve in the second half of 2026 [47][110]. - **Tariff Changes**: Uncertainty surrounding tariff changes is acknowledged, with ongoing efforts to assess their impact on the business [99][100]. Conclusion - Baxter International is positioned at a pivotal point, focusing on stabilizing operations, improving financial performance, and driving innovation. The company aims to build credibility with stakeholders through consistent execution and strategic growth initiatives as it moves into 2026 [145][151].

Core Insights - The Artisan Value Income Fund achieved a return of 2.21% in Q4 2025 and finished the year with a total return of 10.03% for the investor class [5] - Over the past three years, the portfolio has generated an approximate annualized return of 10% [5] Performance Summary - The portfolio's Q4 return was 2.21% [5] - The total return for the year was 10.03% for the investor class [5] - The annualized return over the last three years is around 10% [5]